Cabozantinib (XL184), a multi-targeted oral tyrosine kinase inhibitor with activity against MET, VEGFR2, AXL, and other tyrosine kinases, was assessed in a cohort of metastatic breast cancer (MBC) patients in a phase II randomized discontinuation trial (RDT).Patients received 100 mg cabozantinib daily during a 12-week lead-in stage. Those with stable disease per modified Response Evaluation Criteria in Solid Tumors version 1.0 at 12 weeks were randomized to either continue cabozantinib or receive placebo. Primary endpoints were objective response rate (ORR) during the 12-week lead-in stage and progression-free survival (PFS) after randomization. Patients were also followed for overall survival (OS).Forty-five patients with MBC and a median of three prior lines of chemotherapy for metastatic disease were enrolled. The ORR during the lead-in stage was 13.6 

作者：Sara M, Tolaney；Hovav, Nechushtan；Ilan-Gil, Ron；Patrick, Sch?ffski；Ahmad, Awada；Chris A, Yasenchak；A Douglas, Laird；Bridget, O'Keeffe；Geoffrey I, Shapiro；Eric P, Winer

来源：Breast cancer research and treatment 2016 年 160卷 2期